ArticleOncotarget2017
Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Mutational profile of atypical fibroxanthoma and pleomorphic dermal sarcoma further expands the spectrum of genomic alterations in rare cutaneous neoplasms.Scientific reports · 2026Article
- Article
- Characterization and clinical relevance of PDGFRA pathway copy number variation gains across human cancers.Molecular genetics and genomics : MGG · 2022Article
- Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas.Frontiers in oncology · 2022Review
- Hemato-Oncological Diseases as Risk Factor for Recurrence or Metastasis of Pleomorphic Dermal Sarcoma.Frontiers in oncology · 2022Article
- The clinicopathologic spectrum and genomic landscape of de-/trans-differentiated melanoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Article
- CD10 and p63 expression in a sarcomatoid undifferentiated melanoma: A cautionary (and molecularly annotated) tale.Journal of cutaneous pathology · 2020Article
- Dermal Pleomorphic Sarcoma of the Scalp - Report of Two Cases.Open access Macedonian journal of medical sciences · 2019Article
- [Atypical fibroxanthoma and pleomorphic dermal sarcoma].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2019Review
- Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy.Cancer immunology, immunotherapy : CII · 2019Article
- HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.BMC cancer · 2019Article
- Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype.Clinical sarcoma research · 2019Article
- Article
- First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical fibroxanthomas (AFX) and pleomorphic dermal sarcomas (PDS) are frequent cutaneous sarcomas typically arising on sun-exposed skin in elderly patients. In contrast to AFX, which generally do not recur after complete excision, PDS locally recur in up to 50% and metastasize in up to 20%. We recently detected characteristic UV-induced
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.